OPCH

Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends.

Halper Sadeh LLC, an investor rights law firm, is investigating PTC Inc. and Option Care Health, Inc. for potential violations of federal securities laws and breaches of fiduciary duties relating to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits or terms limiting competing offers are present in these transactions.

Zacks identifies Option Care Health (OPCH) as an attractive value stock opportunity, holding a Zacks Rank #2 (Buy) and Value grade of A. The company trades at a P/E ratio of 15.09, below its industry average of 18.05, and demonstrates favorable valuations across multiple metrics including P/B, P/S, and P/CF ratios compared to industry peers.